SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indevus Pharmaceuticals (NasdaqNM:IDEV)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harold Engstrom who wrote (20)8/2/2004 1:48:02 PM
From: Sidney Street  Read Replies (2) of 78
 
IDEV IR says that it can be assumed that on 12/1 IDEV will exercise its right to switch the arrangement to a royalty-based deal; the guidance being given is that it is a "mid-teens to mid-twenties" percent royalty, plus reimbursement for some of the cost of IDEV's specialty sales force selling into urology, ob/gyn, and high prescriber practices.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News